DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
| Revenue (TTM) | $4.97B |
| Gross Profit (TTM) | $3.10B |
| EBITDA | $1.40B |
| Operating Margin | 24.30% |
| Return on Equity | 38.50% |
| Return on Assets | 10.30% |
| Revenue/Share (TTM) | $12.87 |
| Book Value | $6.95 |
| Price-to-Book | 12.92 |
| Price-to-Sales (TTM) | 6.74 |
| EV/Revenue | 6.71 |
| EV/EBITDA | 21.37 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $377.36M |
| Float | $375.96M |
| % Insiders | 0.27% |
| % Institutions | 106.33% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
GRMN, LTH and DXCM tap the health and fitness boom through premium clubs, connected wearables and glucose sensing as wellness demand grows.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growth, and raised FY26 guidance. DXCM's growth drivers include G7 system adoption, international expansion, and initiatives like 'Road to 100' targeting broader diabetes coverage. Margin improvements, ongoing share buybacks, and a robust balance sheet support DXCM's growth and capital allocation strategy.
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DXCM and any ticker you trade — then tracks every position and per-strategy win rate.
